Modern Decentralized Trials Demand Advanced eClinical Support

By David Blackman, Oracle Health Sciences

In recent years, the biopharmaceutical industry began charting a new course on how to mitigate unprecedented cost and timeline increases, but the advent of COVID-19 thrust decentralized trials (DCTs) into greater prominence, complicating the industry’s evolution. Many organizations have yet to discover a way to integrate these new methods into their existing systems in a way that's both scalable and efficient.
DCTs and other trials thoughtfully implementing digital methods offer the industry its greatest chance of delivering life-saving therapies to patients more quickly and at reduced cost. But seizing their potential requires solving some of the operational, data, and setup problems that current technologies have caused or contributed to.
Using disparate solutions to meet different functional needs has led to a modern industry dependent on numerous siloed solutions, stitched together (i.e., point-to-point integrations) atop aging infrastructure. The result is a highly fragmented user experience, data redundancy, duplication of efforts, and quality issues. Hybrid and decentralized trials, specifically, require more complex integrations to provide real-world data, genomics, patient engagement and, ultimately, decision-driving insights.
Oracle’s Clinical One platform is a next-generation solution intended to break down the silos. It also was designed to offer the ease-of-use and flexibility to easily adapt to industry changes, which includes avoiding painful upgrades and data migrations. Clinical One also facilitates access to clean, quality data — which already is interoperable — by key study stakeholders, promoting faster decision-making and enhanced patient safety through more robust study oversight.